Irritable bowel syndrome
Drug research and approvals for irritable bowel syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 111 studies of irritable bowel syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 7 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 111
- Trials authorized in Canada: 7
- FDA orphan approvals: 0
- EU medicines: 1
- Individualized Brain Stimulation for Irritable Bowel Syndrome With Depressive SymptomsNCT07939698 · Not applicable · The Affiliated Hospital of Hangzhou Normal University · starts Dec 1, 2024
- The LITTLE OWLS Study (in German: "Kleine Eulen OWL"): Exploring the Early-life Microbiome Development and Physical and…NCT07934654 · Not reported · Bielefeld University · starts Mar 1, 2024
- Abdominal Symptoms and Rosacea: An Observational Study on the Association Between Irritable Bowel Syndrome (IBS) and…NCT07922668 · Not reported · IRCCS Azienda Ospedaliero-Universitaria di Bologna · starts Sep 1, 2026
- Lactic Acid Bacteria in Functional Diarrheal DisordersNCT07916688 · Not applicable · Szeged University · starts Nov 1, 2026
- Role of Vitamin D Supplementation in Children With Irritable Bowel SyndromeNCT07914478 · Not applicable · Aziz Bhatti Shaheed Teaching Hospital · starts Sep 1, 2026
- Relationship Between Interoception and Postural Control in Constipation-Predominant Irritable Bowel SyndromeNCT07870915 · Not reported · Saglik Bilimleri Universitesi · starts Oct 1, 2026
- Transauricular Neurostimulation for Abdominal Pain Due to DGBINCT07798180 · Not applicable · Nationwide Children's Hospital · starts Oct 23, 2025
- Herbal Supplement (Biocidin REMOVE) for Bacterial Overgrowth in Irritable Bowel SyndromeNCT07768267 · Phase 2 · Johns Hopkins University · starts Oct 26, 2026
- Kimchi Powder on Gut HealthNCT07749092 · Not applicable · Pusan National University Yangsan Hospital · starts Aug 3, 2026
Approved 8
- LinaclotideHeat-stable enterotoxin receptor agonist
- EluxadolineMu opioid receptor agonist
- TenapanorSodium/hydrogen exchanger 3 inhibitor
- LubiprostoneChloride channel protein 2 opener
- AlosetronSerotonin 3a (5-HT3a) receptor antagonist
- Clindamycin phosphateBacterial 70S ribosome inhibitor
- TegaserodSerotonin 4 (5-HT4) receptor partial agonist
- DicyclomineMuscarinic acetylcholine receptor M3 antagonist
Phase 3 12 of 21
- RifaximinBacterial DNA-directed RNA polymerase inhibitor
- MesalamineArachidonate 5-lipoxygenase inhibitor
- PlecanatideHeat-stable enterotoxin receptor agonist
- IbodutantNeurokinin 2 receptor antagonist
- RamosetronSerotonin 3 (5-HT3) receptor antagonist
- AsimadolineKappa opioid receptor agonist
- EthosuximideVoltage-gated T-type calcium channel blocker
- GlucosamineSupplement
- Lactobacillus acidophilusProbiotic
- RenzaprideSerotonin 3 (5-HT3) receptor antagonist
- Maltodextrin
- OndansetronSerotonin 3a (5-HT3a) receptor antagonist
Phase 2 12 of 40
- EmicerfontCorticotropin releasing factor receptor 1 antagonist
- DronabinolCannabinoid CB1 receptor agonist
- OlorinabCannabinoid CB2 receptor agonist
- DNK333Neurokinin 1 receptor antagonist
- ONO-2952Translocator protein antagonist
- BOS-589Tyrosine-protein kinase receptor RET inhibitor
- PumosetragSerotonin 3 (5-HT3) receptor partial agonist
- CitalopramSerotonin transporter inhibitor
- DoxepinNorepinephrine transporter inhibitor
- EscitalopramSerotonin transporter inhibitor
- FentanylMu opioid receptor agonist
- MilnacipranSerotonin transporter inhibitor
Phase 1 or earlier 10
- GSK-3179106
- MexiletineSodium channel alpha subunit blocker
- CholecalciferolVitamin D receptor agonist
- OctreotideSomatostatin receptor agonist
- NitazoxanidePyruvate:ferredoxin oxidoreductase inhibitor
- AcetylcysteineGlutathione precursor
- Polyethylene glycolOsmotic laxative
- DA-6886
- ROSE-010
- Histidine
How its trials ended
982 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 202 whose ending is known, 57% met their primary endpoint, 6% missed it and 37% stopped early.
- Completed, result not reported45046%
- Ongoing18419%
- Status unknown14615%
- Met its primary endpoint11512%
- Stopped: other or unclear404%
- Stopped: enrollment or feasibility212%
- Missed its primary endpoint121%
- Stopped: lack of efficacy51%
- Stopped: sponsor or business decision51%
- Stopped: safety2<1%
- Stopped: funding2<1%
| Apr 17, 2026 | A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of brenipatide in the treatment of adult participants with…Brenipatide (LY3537031) | Eli Lilly | Ongoing |
| Mar 20, 2026 | A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of brenipatide in the treatment of adult participants with…Brenipatide (LY3537031) | Eli Lilly | Ongoing |
| Apr 10, 2024 | A phase 2, multicenter, randomized, placebo-controlled, double-blind induction study to evaluate the efficacy and safety of oral TAK-279 in subjects with…Zasocitinib (TAK-279, NDI-034858) | Takeda Pharmaceuticals USA | Ongoing |
| Aug 27, 2021 | Understanding the neurocognitive effects of fecal microbiota transplantation in major depressive disorder patients with and without irritable bowel syndromeIntestinal microbes recovered from filteration, suspension and ultrafiltration… | Governors of The University of Calgary | Pending |
| Mar 5, 2020 | A phase 3, open-label, long-term safety study of oral linaclotide administered to pediatric participants with functional constipation (FC) or irritable bowel…Linaclotide (constella) | AbbVie | Ongoing |
| Dec 19, 2017 | A phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the safety and efficacy of eluxadoline in pediatric…Eluxadoline | AbbVie | Closed |
| Feb 5, 2015 | Manipulating the microbiome in inflammatory bowel disease (IBD) by antibiotics: a multicentre randomized controlled trial.Vancomycin/ Amoxicillin/ Metronidazole/ Doxycycline | The Hospital for Sick Children | Closed |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Nov 26, 2012 | ConstellaLinaclotide | AbbVie Deutschland GmbH & Co. KG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA